Nuwellis Inc (NUWE)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $2.65M
Last updated: Nov 17, 2026 at 11:03 AM ET
Nuwellis Inc (NUWE) Earnings: Report Dates and Results
Nuwellis (NUWE) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Nuwellis reported EPS of -$5.81, above the -$122.85 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NUWE has an expected report date of Mar 8, 2027.
NUWE Earnings Call
The latest NUWE earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, NUWE beat 11, missed 10 and matched 18. Revenue for the quarter ended Sep 30, 2026 was $2.21M, down 0.5% from $2.22M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$5.81 | -$122.85 | N/A | +95.27% | Beat | -129.6% | 1 | 0 up, 1 down | Nov 12, 2026 | $2.21M |
| Jun 30, 2026 | -$26.64 | -$23.80 | N/A | -11.93% | Miss | N/A | 1 | 0 up, 1 down | Aug 13, 2026 | $1.97M |
| Mar 31, 2026 | -$73.15 | -$35.00 | N/A | -109.00% | Miss | N/A | 1 | 1 up, 0 down | May 12, 2026 | $2.40M |
| Dec 31, 2025 | -$1.50 | -$1.56 | N/A | +3.85% | Beat | N/A | N/A | N/A | Mar 10, 2026 | $2.42M |
| Sep 30, 2025 | $19.60 | -$602.70 | N/A | +103.25% | Beat | -99.2% | N/A | 0 up, 0 down | Nov 12, 2025 | $2.22M |
| Jun 30, 2025 | -$2,134.65 | -$661.50 | N/A | -222.70% | Miss | N/A | N/A | 0 up, 0 down | Aug 14, 2025 | $1.73M |
| Mar 31, 2025 | -$1,014.30 | -$661.50 | N/A | -53.33% | Miss | N/A | N/A | 0 up, 0 down | May 13, 2025 | $1.90M |
| Dec 31, 2024 | -$0.44 | -$0.43 | N/A | -2.33% | Miss | N/A | N/A | 0 up, 0 down | Mar 11, 2025 | $2.32M |
| Sep 30, 2024 | $2,557.81 | -$1,881.60 | -$2,468.12 - -$1,292.82 | +235.94% | Beat | N/A | 2 | 0 up, 0 down | Nov 11, 2024 | $2.37M |
| Jun 30, 2024 | -$27,709.56 | -$12,120.18 | -$13,941.94 - -$10,283.83 | -128.62% | Miss | N/A | 2 | 0 up, 0 down | Aug 13, 2024 | $2.19M |
| Mar 31, 2024 | -$0.60 | -$1.06 | -$1.06 - -$1.06 | +43.40% | Beat | N/A | 1 | 0 up, 0 down | May 7, 2024 | $1.86M |
| Dec 31, 2023 | -$115,248.35 | -$71,515.71 | -$113,522.84 - -$45,717.34 | -61.15% | Miss | N/A | 3 | 0 up, 0 down | Mar 5, 2024 | $2.55M |
| Sep 30, 2023 | -$93,124.78 | -$160,181.48 | -$166,431.68 - -$154,103.40 | +41.86% | Beat | N/A | 3 | 0 up, 0 down | Nov 7, 2023 | $2.41M |
| Jun 30, 2023 | -$187,793.06 | -$207,001.12 | -$224,477.29 - -$181,328.34 | +9.28% | Beat | N/A | 3 | 0 up, 0 down | Aug 8, 2023 | $2.08M |
| Mar 31, 2023 | -$261,820.06 | -$430,123.29 | N/A | +39.13% | Beat | N/A | 3 | 0 up, 0 down | May 9, 2023 | $1.83M |
| Dec 31, 2022 | -$5.00 | -$17.09 | -$36.00 - -$13.31 | +70.74% | Beat | N/A | 2 | 0 up, 0 down | Feb 28, 2023 | $2.34M |
| Sep 30, 2022 | -$1,000,000.00 | -$1,000,000.00 | -$2,157,447.65 - -$667,781.42 | 0.00% | In line | N/A | 3 | 1 up, 0 down | Nov 8, 2022 | $2.06M |
| Jun 30, 2022 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | $2.21M |
| Mar 31, 2022 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 3 | 2 up, 0 down | May 10, 2022 | $1.93M |
| Dec 31, 2021 | -$41.00 | -$47.67 | -$51.00 - -$41.00 | +13.99% | Beat | N/A | 3 | 0 up, 0 down | Mar 1, 2022 | $1.64M |
| Sep 30, 2021 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 3 | N/A | Nov 9, 2021 | $1.85M |
| Jun 30, 2021 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 10, 2021 | $2.51M |
| Mar 31, 2021 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | May 11, 2021 | $1.92M |
| Dec 31, 2020 | -$157.00 | -$191.00 | N/A | +17.80% | Beat | N/A | N/A | N/A | Mar 2, 2021 | $2.04M |
| Sep 30, 2020 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 10, 2020 | $1.90M |
| Jun 30, 2020 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 4, 2020 | $1.86M |
| Mar 31, 2020 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | May 12, 2020 | $1.63M |
| Dec 31, 2019 | -$3,360.00 | -$2,400.00 | N/A | -40.00% | Miss | N/A | N/A | N/A | Mar 3, 2020 | $1.37M |
| Sep 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 5, 2019 | $1.25M |
| Jun 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 6, 2019 | $1.68M |
| Mar 31, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | May 7, 2019 | $1.22M |
| Dec 31, 2018 | -$25,110.00 | -$22,680.00 | N/A | -10.71% | Miss | N/A | N/A | N/A | Feb 20, 2019 | $1.50M |
| Sep 30, 2018 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 6, 2018 | $1.36M |
| Jun 30, 2018 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 7, 2018 | $1.10M |
| Mar 31, 2018 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | May 8, 2018 | $1.04M |
| Dec 31, 2017 | -$187,320.00 | -$52,920.00 | N/A | -253.97% | Miss | N/A | N/A | N/A | Mar 20, 2018 | $831000 |
| Sep 30, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Oct 31, 2017 | $957000 |
| Jun 30, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 8, 2017 | $864000 |
| Mar 31, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | May 9, 2017 | $901000 |
| Dec 31, 2016 | -$38,976.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 2, 2017 | $746000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3,130.85, after -$25,152.79 the year before. It was -$3,038,976.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3,130.85 | N/A |
| Dec 31, 2024 | -$25,152.79 | N/A |
| Dec 31, 2023 | -$657,986.25 | N/A |
| Dec 31, 2022 | -$3,000,005.00 | N/A |
| Dec 31, 2021 | -$3,000,041.00 | N/A |
| Dec 31, 2020 | -$3,000,157.00 | N/A |
| Dec 31, 2019 | -$3,003,360.00 | N/A |
| Dec 31, 2018 | -$3,025,110.00 | N/A |
| Dec 31, 2017 | -$3,187,320.00 | N/A |
| Dec 31, 2016 | -$3,038,976.00 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,200 words across 4 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,177 | 4 | |
| 2026Q1 | Mar 31, 2026 | 2,512 | 5 | |
| 2025Q4 | Dec 31, 2025 | 2,823 | 5 | |
| 2025Q2 | Jun 30, 2025 | 1,758 | 5 | |
| 2025Q1 | Mar 31, 2025 | 2,481 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,135 | 7 | |
| 2024Q2 | Jun 30, 2024 | 2,719 | 6 |
2026Q3 Earnings Call
Opening remarks
Leah McMullen Director of Communications Thank you, operator. Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the third quarter of 2026. Joining me today are Mike McCormick, Nuwellis' President and Chief Executive Officer, and Carisa Schultz, Chief Financial Officer. Earlier today, Nuwellis released its third quarter 2026 financial results. If you have not received the earnings release, please visit the Investors page of the company's website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and the company assumes no obligation to update these statements. Accordingly, you should not place any undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company's filings with the Securities and Exchange Commission, including the latest 10-K. With that, I would now like to turn the call over to Mike McCormick, Nuwellis' CEO.
Michael McCormick President and Chief Executive Officer Thank you, Leah, and good morning, everyone. On our last conference call, I outlined three priorities for Nuwellis. First, to increase Aquadex utilization and recurring circuit revenue; second, to build on our strong position in pediatrics and expand our presence in adult critical care; and third, to strategically broaden our cardiorenal platform through technologies and collaborations that complement Aquadex and leverage our existing customer relationships. From a financial standpoint, we made meaningful progress in the quarter, improving our operating performance. Third-quarter gross margin expanded 430 basis points, while operating expenses declined 13% year over year, resulting in a 24% improvement in operating loss. These results reflect our continued focus on disciplined spending, improved operating efficiency, and directing resources toward the highest-priority growth initiatives. The expansion of our installed base remains one of our most important indicators of our commercial progress. During the first nine months of 2026, we sold 32 Aquadex consoles. That's an 88% increase compared with 17 consoles during the same period last year. In the third quarter, we sold eight consoles compared with 12 in the prior-year quarter. Every console added to our installed base expands the opportunity for recurring circuit revenue, and our teams remain focused on increasing utilization across our existing hospital customers. We had a strong first half of 2026.
Frequently Asked Questions About NUWE
When is Nuwellis's next earnings date?
Nuwellis's next earnings report is expected for Mar 8, 2027.
Did NUWE beat earnings estimates last quarter?
Yes. Nuwellis reported EPS of -$5.81 for the quarter ended Sep 30, 2026, above the -$122.85 estimate, a 95.27% surprise.
What EPS do analysts expect from NUWE next quarter?
The consensus EPS estimate for Nuwellis for the quarter ending Dec 31, 2026 is -$0.34 from 3 analysts.
How often does NUWE beat earnings estimates?
Nuwellis beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -24.62%.
NUWE pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts